The Neurovirology Unit conducts research on the acute and long-term complications associated with human alphaherpesvirus infections and pulmonary infections caused by coronaviruses and influenza.
Using transgenic animal models and integrating approaches from molecular virology, neurobiology, and immunology, we investigate the mechanisms underlying viral pathogenesis in the central nervous system, which particularly involves analyzing roles of immunomodulatory host factors to understand their roles in pathogenesis, neuroprotection, and potentiating antiviral immunity. While studying different aspects of antiviral immunity, we also focus on understanding the neurological regulation of antiviral immunity, neuroinflammation, and the long-term manifestations of viral infection, such as neurodegeneration and cognitive decline using machine learning-based behavioral approaches.
Additionally, the Neurovirology Unit explores the interactions between viral proteins, host factors, and immune responses that drive differential disease severity observed in humans, paving the way for innovative therapeutic strategies. We are also committed to advancing human brain and lung organoid models to recapitulate disease phenotypes in humans and thereby enhance our understanding of viral disease mechanisms.
Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Gascon R, Tsou CL, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Morris MK, Wadford D, Hanson C, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna JA, Ott M. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022 Jul;607(7918):351-355.
Ryu JK, Yan Z, Montano M, Sozmen EG, Dixit K, Suryawanshi RK, Matsui Y, Helmy E, Kaushal P, Makanani SK, Deerinck TJ, Meyer-Franke A, Rios Coronado PE, Trevino TN, Shin MG, Tognatta R, Liu Y, Schuck R, Le L, Miyajima H, Mendiola AS, Arun N, Guo B, Taha TY, Agrawal A, MacDonald E, Aries O, Yan A, Weaver O, Petersen MA, Meza Acevedo R, Alzamora MDPS, Thomas R, Traglia M, Kouznetsova VL, Tsigelny IF, Pico AR, Red-Horse K, Ellisman MH, Krogan NJ, Bouhaddou M, Ott M, Greene WC, Akassoglou K. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024 Sep;633(8031):905-913.
Suryawanshi RK, Patil CD, Agelidis A, Koganti R, Ames JM, Koujah L, Yadavalli T, Madavaraju K, Shantz LM, Shukla D. mTORC2 confers neuroprotection and potentiates immunity during virus infection. Nat Commun. 2021 Oct 14;12(1):6020.
Suryawanshi RK, Patil CD, Agelidis A, Koganti R, Yadavalli T, Ames JM, Borase H, Shukla D. Pathophysiology of reinfection by exogenous HSV-1 is driven by heparanase dysfunction. Sci Adv. 2023 Apr 28;9(17):eadf3977.
Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Zapatero-Belinchón FJ, McCavittMalvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Richards AL, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2. eLife14:RP103484.
Suryawanshi R, Ott M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?. Nat Rev Immunol. 2022 Oct;22(10):591-592.
- Acute and post-acute neuropathies of virus infections
- Impact of genetics on disease severity
- Host-virus interactions and its effect on antiviral immunity
- Human brain and lung organoid models to study virus infection
Anti-(idio)typical: A New Immunogen to Vaccinate Against RSV
Going Straight to the Source in Defense Against Infant RSV
Study Reveals Best Timing for Getting the RSV Vaccine During Pregnancy to Protect Newborns
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Contact Information
Office/Contact: Research Coordinator
Phone: 203-785-5474
Researchers Discover Antibody that Neutralizes both RSV and hMPV
Diagnostics Development Services
Study Finds Early RSV Infection Linked to Significantly Increased Risk of Asthma in Children
NIH Celebrates FDA Approval of RSV Vaccine for People 60 Years of Age and Older
Contact
Submit a Media Request
Contact the NIAID News & Science Writing Branch.